Teprotumumab

Teprotumumab was approved for the treatment of thyroid eye disease in January 2020. As real-world experience with teprotumumab increases, several clinical reports describing patient responses, safety and effectiveness are now appearing.

Not everyone can agree on what to call thyroid eye disease.

Thyroid eye disease was first described by Robert James Graves, FRCS, an Irish surgeon who recognized the association of hyperthyroidism with exophthalmos in 1835. Even today, many use Graves’ ophthalmopathy when discussing this disease.

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Roger A. Dailey, MD, discusses outcomes in patients treated for thyroid eye disease with traditional methods and teprotumumab.

WAILEA, Hawaii — In this video from Hawaiian Eye, Wendy W. Lee, MD, and Roger A. Dailey, MD, discuss the latest information surrounding diagnosis and management of thyroid eye disease.

Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.

Horizon Therapeutics has received a prior approval supplement for its previously approved biologics license application so that it can manufacture more Tepezza for the treatment of thyroid eye disease, according to a press release.

The COVID-19 pandemic has abruptly affected drug manufacturing in the United States. This now includes the production of Tepezza, the only FDA-approved medical therapy for thyroid eye disease.

Despite the COVID-19 pandemic, the FDA approved 47 new molecular entities in 2020, including one for ophthalmology, compared with 48 in 2019, according to a speaker at the virtual Ophthalmology Innovation Summit Year in Review meeting.

Additional data from the OPTIC-X extension trial and pooled analysis of phase 2 and 3 trial data confirm the efficacy of teprotumumab for the treatment of thyroid eye disease in the longer term and at different degrees of disease severity.